Introduction
Prostate cancer is the most common malignancy and the second leading cause of cancer mortality in men (Jemal et al., 2008) . Chemotherapy and androgen withdrawal are used for slowing down the spread of the disease but currently there are no effective treatments for advanced prostate cancer. Therefore, better understanding of cancer cell survival mechanisms and more efficient therapy forms are required for treatment of prostate cancer. In this regard, death receptor ligands, with capacity to activate apoptosis or programmed cell death specifically in cancer cells, have been suggested as one possible treatment approach (reviewed by Fulda and Debatin, 2004) .
Activation of the tumor necrosis factor family death receptors, such as the Fas receptor (CD95/APO-1/ DR6) and the tumor necrosis factor-related apoptosisinducing ligand (TRAIL) receptors 1 and 2 (DR4 and DR5), initiates apoptosis through the extrinsic signaling pathway. The cytoplasmic death-inducing signaling complex (DISC) that is formed to the activated death receptors serves as a platform for activation of the initiator cysteine proteases caspase-8 and caspase-10 ( Kischkel et al., 1995; Muzio et al., 1996; Vincenz and Dixit, 1997) . The proteolytic activity of the downstream effector caspases leads to apoptosis of the cell. Various damaging stresses trigger the so-called intrinsic pathway of apoptosis. This signaling pathway involves the Bcl-2 family proteins that control mitochondrial integrity, cytochrome c release and activation of caspase-9 (Danial and Korsmeyer, 2004) . The death receptor-mediated extrinsic and the mitochondrial intrinsic apoptosis pathways are connected through Bid, a member of the Bcl-2 family proteins, which is a substrate for caspase-8. When Bid becomes cleaved by activated caspase-8, its truncated form (tBid) translocates to the mitochondria in which it induces the release of cytochrome c and other proapoptotic factors (reviewed in Sprick and Walczak, 2004) . The main site of death ligand expression is the immune system in which NK and T cells use them for killing transformed or infected cells (reviewed in Schaefer et al., 2007) . TRAIL or Fas ligand-induced apoptosis is thereby an important mechanism in the immune surveillance against transformed, potentially carcinogenic cells and, consequently, successful cancer cells usually develop resistance against death receptor stimulation.
The use of Fas ligand as a potential anti-neoplastic agent has got into a halt because of induction of severe liver damage (Ogasawara et al., 1993) . However, the focus has turned to TRAIL because it has been shown to induce apoptosis in a range of different tumor cell lines with minimal pro-apoptotic effects in normal cells. This has lead to extensive research to use TRAIL in treatment of cancer. Several studies have now shown that TRAIL-based therapies show selective antitumor activity in mouse models of colon, glioma, lung and prostate cancer, and multiple myeloma (reviewed in Koschny et al., 2007) . More importantly, recombinant human TRAIL and human monoclonal agonistic TRAIL receptor antibodies are currently analysed in phase Ib/II clinical trials for cancer therapy. The early clinical trials are promising and no toxicity has been observed in human patients treated with TRAIL or agonistic antibodies (reviewed by Mahalingam et al., 2008) . However, targeting of TRAIL receptors alone appears not to be potent enough to kill all cancer cell types and combination with other sensitizing agents might be needed to induce efficient tumor cell apoptosis.
Prostate tumors express frequently TRAIL receptors on the cell surface, but these receptors are often not able to trigger TRAIL-induced apoptosis because of increased pro-survival signaling (Bucur et al., 2006) . Research is now focused on discovering combinatorial therapies with agents that reduce TRAIL resistance but do not harm normal tissues. Lignans are dietary phytoestrogens (reviewed by Adlercreutz, 2007) that have shown cancer preventive and antitumorigenic activity, and thereby may show potential as TRAILsensitizing agents. It has been shown that lignans inhibit proliferation and are cytotoxic to prostate cancer cell lines (Lin et al., 2001 , Chen et al., 2007 . Moreover, lignans can prevent tumor growth and induce apoptosis in vivo in prostate cancer xenografts or chemically induced mammary tumors (Bylund et al., 2005; Saarinen et al., 2008; Thompson et al., 1996) and can also reduce experimental metastasis (Li et al., 1999) . Plant-derived lignans, such as matairesinol (MAT), are metabolized by mammalian gut microflora resulting in enterolactone (ENL) or enterodiol (Axelson et al., 1982) . As a result of their promising antitumorigenic effects, we wanted to test whether lignans could be used as therapeutic agents, to counteract cancer cell resistance to TRAIL.
The purpose of this study was to examine whether lignans could enhance death receptor signaling to enable TRAIL-based therapies in prostate cancer. To this end, we used the TRAIL-resistant LNCaP cell model for androgen-sensitive stages of prostate cancer (Nesterov et al., 2001) . When screening the lignans for TRAIL sensitization, we observed that MAT was especially efficient in sensitizing cancer cells to TRAIL receptormediated apoptosis. MAT-sensitized LNCaP cells to TRAIL through increased cleavage of Bid, amplified mitochondrial depolarization and facilitated caspase activation. The sensitization was dependent on downregulation of the phosphatidylinositol 3-kinase (PI3K)/ Akt survival pathway activity. These results suggest that sensitization to death receptor-mediated apoptosis by inhibition of Akt activity is a key molecular mechanism by which lignans exert their anticancer effects. The presented concept of cancer therapy could be practicable in developing therapies against androgen-dependent prostate tumors.
Results

Lignans sensitize LNCaP prostate cancer cells to TRAIL-induced apoptosis
Earlier reports show that androgen-dependent LNCaP prostate cancer cells are TRAIL resistant (Nesterov et al., 2001; Thakkar et al., 2001) , although treatment with the ENL lignan inhibited their proliferation (McCann et al., 2008) and induced cell death after prolonged exposure (Chen et al., 2007) . As it is well documented that plant lignans also have potent antitumorigenic activity with minimal side effects (Thompson et al., 1996; Bylund et al., 2005; Saarinen et al., 2008) , we tested whether this activity could involve sensitization to death receptor signaling. A number of closely related lignans ( Figure 1a ) were tested in a non-toxic concentration for their capacity to sensitize LNCaP prostate cancer cells to TRAIL receptor-mediated apoptosis in the prescence or absence of androgen. When comparing the effects of hydroxymatairesinol, ENL and MAT, the results of nuclear fragmentation assay showed that both ENL and especially MAT were efficient in sensitizing the cells to TRAIL receptor signaling (Figure 1b ). Hydroxymatairesinol had no effect on TRAIL-induced apoptosis. The sensitizing effect of MAT was more pronounced in androgen-deprived cells but observable also in the androgen-supplied samples that show stronger resistance toward TRAIL treatment. At 40 mM, none of the used compounds induced apoptosis in 20 h when administered alone. We also consistently observed inhibition of cell proliferation by MAT, which corroborates previous work by McCann et al. (2008) (data not shown). Furthermore, longer pretreatment (24 h) with 40-100 mM MAT was able to some extent enhance TRAIL-induced apoptosis in leukemic Jurkat T cells and HeLa cells, two TRAIL-sensitive cancer cell lines included for comparison (Supplementary Figure 1) . The prolonged pretreatment with hydroxymatairesinol, ENL or MAT could also sensitize HeLa cells to Fas receptormediated apoptosis, suggesting that the mechanism behind the sensitizing effect may be common for different death receptors (Supplementary Figure 2) .
MAT sensitizes LNCaP cells effectively to TRAIL but does not enhance doxorubicin-induced apoptosis As MAT was found to be the most efficient of the tested lignans in sensitization of LNCaP cells to TRAILinduced apoptosis, we examined the concentration dependence of the effect. Androgen-deprived or supplied LNCaP cells were treated with 0-100 mM MAT for 1 h before addition of 10 ng/ml izTRAIL (Figure 2a) . After 20 h, the percentage of cells with activated caspase-3 was detected by flow cytometry. Already 10 mM MAT enhanced TRAIL-induced apoptosis but more pronounced effect was observed with 40-100 mM MAT. To reduce the possibility of MAT-induced cytotoxicity with high concentrations, we continued the experiments with 40 mM MAT, as in androgensupplemented cells the almost maximal sensitizing effect was already observed with this dose. When 40 mM MAT was combined to increasing doses of izTRAIL, both androgen-deprived and androgen-supplied LNCaP cells underwent apoptosis (caspase-3 activation) with lower TRAIL concentrations and higher maximum apoptosis percentage was reached (Figure 2b ). Combination of 40 mM MAT to 10 ng/ml izTRAIL also increased nuclear fragmentation that was observed by fluorescence microscopy of LNCaP cells (Figure 2c ).
To test whether the observed effect was specific to receptor-mediated apoptosis, we combined MAT treatment with doxorubicin, a common cancer drug for prostate cancer that induces apoptosis by transcriptional inhibition. Although TRAIL-induced polymerase cleavage was amplified by MAT, such an effect was not observed in doxorubin-induced apoptosis (Figure 2d ). In contrast to these results with the androgen-responsive LNCaP cell line, the same pretreatment with 40 mM MAT could not markedly enhance TRAIL-induced apoptosis in the androgen-independent and TRAIL-sensitive PC3 prostate cancer cells (Supplementary Figure 3) .
Surface expression of TRAIL receptors or TRAIL-DISC formation is not increased in MAT-treated LNCaP cells
To determine the molecular mechanisms underlying the effects of MAT on TRAIL-receptor signaling, we studied different components of the death receptor signaling pathway. Expression of TRAIL receptors and decoy receptors on the cell surface regulates cellular responsiveness to TRAIL (Pan et al., 1997; Sheridan et al., 1997; Jin et al., 2004) . To survey the possibility that MAT induces sensitization by increased TRAIL-R or decreased decoy-receptor expression, the amount of DR4 (TRAIL-R1), DR5 (TRAIL-R2) and TRAIL decoy receptors (DcR1 and DcR2) expression on the cell surface was analysed by flow cytometry in LNCaP cells. The results in Figure 3a show no increase of DR4 or DR5 expression and no decrease in DcR1 or DcR2 expression after 1-to 24-h incubation with 40 mM MAT. Instead, MAT treatment decreased DR4 expression in both androgen-deprived and androgen-supplemented cells. Androgen, on the other hand, increased both DR4 and DR5 expression (Figure 3a) , an effect that did not correlate with TRAIL sensitivity. After treatment with 40 mM HMR, ENL, MAT or solvent control for 1 h izTRAIL (10 ng/ml) was added to cells. Twenty hours later, the cells were disrupted and the nuclei labeled for DNA content with propidium iodide. The samples were analysed by flow cytometry and the fraction of sub-G0/G1 events (nuclear fragmentation) was detected as a measure of apoptotic cell death (mean ± s.e.m.; n ¼ 3; Student's t-test *Po0.05, **Po0.01).
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TRAIL ( As formation of the DISC protein complex at the intracellular domain of the TRAIL receptors is the first intracellular step of the signaling cascade leading to apoptosis, we examined if MAT increases the amount of DISC formation and subsequent caspase-8 activation. TRAIL-R DISC was induced for 15 or 60 min in androgen-free or androgen-supplemented LNCaP cells that had been preatreated for 1 h with 40 mM MAT or solvent control. After immunoprecipitation of the DR4 and DR5 receptor complexes we detected FADD, caspase-8 and DR5 in the precipitates. MAT neither increased nor prolonged FADD or caspase-8 Lignans sensitize prostate cancer cells to TRAIL E Peuhu et al recruitment to the TRAIL-DISC in androgen treated or androgen-deprived LNCaP cells suggesting that MAT exerts its effect downstream of DISC formation (Figure 3b ). We noticed that TRAIL-DISC formation and caspase-8 activation was somewhat more efficient in androgen-supplied LNCaP cells (Figure 3b) , which supports the reported role of androgen as a mediator of effective TRAIL-DISC formation in LNCaP cells (Rokhlin et al., 2002) . We also examined the protein levels of the major TRAIL-DISC proteins, c-FLIP L/S , caspase-8 and FADD after 5 and 20 h of MAT treatment. Interestingly, a clear decrease in protein levels of both c-FLIP L/S and caspase-8, but not of FADD, was observed after 20-h MAT treatment (Figure 3c ). In any case, this downregulation was observed later than 5-h MAT treatment and thereby is unlikely to affect the composition of the TRAIL-DISC that is induced after 1-h MAT pretreatment. Taken together, these results suggest that MAT does not affect the proximal death receptor signaling, but exerts its effect downstream of TRAIL-DISC formation.
MAT increases TRAIL-induced Bid cleavage and mitochondrial depolarization in LNCaP cells
The involvement of intrinsic cell death signaling in regulation of death receptor responses of LNCaP cells has been shown by sensitization of these cells to TRAILinduced apoptosis by inhibition of anti-apoptotic Bcl-2 proteins (Kim et al., 2005; Ray et al., 2005) . Therefore, we examined whether MAT could increase the activation of intrinsic mitochondrial apoptotic signaling, thereby amplifying death receptor signaling and sensitizing the cells to TRAIL-induced apoptosis. Mitochondrial membrane polarity was evaluated by tetramethylrhodamine labeling 4-24 h after the start of the treatments. The results in Figure 4a show that mitochondrial depolarization was increased if the cells were pretreated with MAT for 1 h before TRAIL receptor ligation. The increase in TRAIL-induced mitochondrial depolarization was more pronounced in the androgen-deprived cells. This result correlates well with the number of apoptotic cells (Figure 2a ). Together these results suggest that the MAT-mediated effect is associated with amplification of the mitochondrial death receptor signaling in response to TRAIL.
As the caspase-mediated cleavage of Bid serves to link the extrinsic and the intrinsic death pathways, we analysed if MAT increases TRAIL-induced Bid cleavage. This was indeed the case in the absence of androgen, as TRAIL alone was unable to induce efficient Bid cleavage, but pretreatment with MAT clearly increased the cleavage (Figure 4b ). In the androgen-supplied LNCaP cells, which have stronger caspase-8 activation after TRAIL treatment, Bid cleavage already occurred with TRAIL treatment alone and was not thereby enhanced further by MAT (Figure 4b) . Nevertheless, the androgen-supplemented cells were found to be more resistant to TRAIL-induced apoptosis (Figure 2b) . Our results show that in the absence of androgen TRAIL-induced apoptosis is suppressed upstream of Bid cleavage and MAT can enhance the cleavage. In the presence of androgen, apoptosis is blocked downstream of Bid cleavage, most likely by hormone-induced survival signals, and MAT treatment might affect other steps in the apoptotic pathway to increase caspase-3 activation in response to TRAIL. Separately, we observed that when caspases were inhibited, downregulation of full size Bid (22 kDa) was not observed, showing that the downregulation is not because of reduction in the protein level, but rather caused by caspase-mediated cleavage (data not shown). The truncated Bid seems to be subjected to active proteasomal degradation, as proteasome inhibition through epoximicin (200 nM) results in generation of the active 15-kDa tBid fragment after TRAIL treatment (data not shown). We could also observe that Bid-green fluorescent protein (GFP) transferred from diffuse cytoplasmic fluorescence to presumably mitochondrial (granular), localization, when MAT was combined to TRAIL treatment (data not shown), further supporting the western blot results in Figure 4b , showing increased Bid cleavage in response to TRAIL when the cells are also treated with MAT.
To evaluate the possibility that MAT affects the mitochondrial signaling pathway by altering protein expression, we examined the expression levels of Bid and other Bcl-2 family proteins after MAT treatment. Incubation with 40 mM MAT did not affect the expression of Bid, the pro-apoptotic Bcl-2 proteins Bax or Bim EL , or the anti-apoptotic BcL-X L (Figure 4 ).
MAT sensitizes LNCaP prostate cancer cells to apoptosis through inhibition of Akt
The LNCaP cells have a high constitutive Akt activity, which appears to protect the cells from TRAIL-induced apoptosis Nesterov et al., 2001; Rokhlin et al., 2002 Rokhlin et al., , 2005 . To analyse the possibility that MAT would sensitize LNCaP cells to TRAIL by inhibiting the PI3K/Akt-pathway, we first analysed whole cell lysates after 1 h of MAT treatment for the levels of phosphorylated Akt (Figure 5a ). The activity of Akt, as measured by the fraction of phospho-Akt from the total amount of Akt, was quantified from the western blots (Figure 5b ). Treatment with MAT rapidly decreased Akt phosphorylation in both androgendeprived and androgen-stimulated LNCaP cells, indicating a possible mechanism for MAT in the sensitization to TRAIL-induced apoptosis. Inhibition of the PI3K with the small molecule inhibitor LY294002 also results in sensitization LNCaP cells to TRAIL-induced apoptosis (data not shown, Chen et al., 2001) . To verify the involvement of the Akt pathway, we transfected LNCaP cells with mock-GFP or constitutively active Akt-GFP (ca-Akt-GFP), and assayed the cells for MAT-mediated sensitization to TRAIL. In the androgen-deprived cells, expression of ca-Akt efficiently reversed the MAT-mediated sensitization to TRAILinduced apoptosis (Figure 5c ). The androgen-stimulated cells became greatly sensitized to TRAIL by the transfection procedure itself and the effect of ca-Akt expression could not be examined in the presence of androgen (data not shown). These results provide evidence that the MAT-mediated inhibition of the PI3K/Akt-pathway indeed is required for the sensitization to TRAIL, particularly in the absence of androgens.
Discussion
In this study, we have shown that lignans can sensitize androgen-dependent LNCaP prostate cancer cells to TRAIL death receptor-mediated apoptosis. Our data show that in LNCaP prostate cancer cells, sensitization to TRAIL by MAT involves increased cleavage of Bid and amplification of the mitochondrial death pathway. MAT downregulates Akt phosphorylation in both androgen-deprived and androgen-stimulated LNCaP cells and MAT-mediated sensitization to TRAIL can be reversed by ectopically increased Akt activity. Together these results imply that MAT inhibits Akt activity and thereby sensitizes LNCaP cells to TRAILinduced apoptosis. In fact, the mechanism underlying LNCaP insensitivity to death receptor stimulation has been shown earlier to involve the PI3K/Akt survival pathway Nesterov et al., 2001; Rokhlin et al., 2002 Rokhlin et al., , 2005 . The constitutive activation of the PI3K/Akt-pathway observed in many cancer Lignans sensitize prostate cancer cells to TRAIL E Peuhu et al forms can be related, for example, to the loss of PTEN, a lipid phosphatase that negatively regulates the pathway (Vlietstra et al., 1998) . Targeting of the PI3K/Aktpathway is therefore of great importance in treatment of prostate cancer. In LNCaP cells, androgen deprivation results in decreased TRAIL-DISC formation and caspase activation (Rokhlin et al., 2002) . We also observed less DR4 and DR5 surface expression as well as somewhat decreased TRAIL-DISC formation and caspase-8 activation in the absence of androgen. Interestingly, MAT treatment could overcome this effect by facilitating TRAIL-induced Bid cleavage and mitochondrial depolarization. MAT did not increase the levels of DR4 or DR5 surface expression, or caspase-8 activation in the DISC. Honokiol, a phenolic neolignan, was recently reported to sensitize non-small cell lung cancer cells to TRAIL by rapid downregulation of c-FLIP L/S expression (Raja et al., 2008) . MAT also decreased c-FLIP L/S protein levels but this downregulation occurred after more than 5-h MAT treatment. As our results also show unaltered TRAIL-DISC formation after MAT treatment, it is unlikely that the increase in TRAIL-induced apoptosis observed with MAT treatment would be caused by increased caspase-8 activation in the DISC. We cannot, however, rule out the possibility that the reduced c-FLIP L/S protein levels could influence the later stages of TRAIL-induced apoptosis. Instead, our data show that MAT enhances TRAIL-induced Bid cleavage in androgen-deprived LNCaP cells. According to Nesterov et al. (2001) and Chen et al. (2001) , Akt mediates TRAIL-resistance of LNCaP cells, which appears to function through inhibition of Bid cleavage. A recent study by Aslan et al. (2009) , describes an intriguing link between Akt activity and the proapoptotic actions of Bid in response to TRAIL treatment. They identified PACS-2, a multifunctional sorting protein, as an Akt substrate that regulates Bid translocation to the mitochondria after TRAIL-receptor activation. Owing to the importance of Akt activity in TRAIL resistance of cancer cells, identification and employment of Akt inhibiting compounds, such as MAT, in combinatorial TRAIL treatments may be essential.
MAT-mediated sensitization of LNCaP cells to TRAIL was less efficient if the cells were cultured with androgen, and the exact mechanism of it remains to be analysed. When androgen was present, Bid cleavage occurred after TRAIL stimulation alone but did not lead to mitochondrial depolarization and apoptosis. Therefore, androgen-induced TRAIL-resistance appears to be conveyed by a mechanism upstream of the mitochondria but downstream of Bid cleavage. Regulation of the apoptosis pathway at this level has not been extensively studied. As the expression of the antiapoptotic Bcl-2 protein is downregulated by androgens (data not shown, Huang et al., 2004) , the mechanism that protects androgen-stimulated cells from mitochondrial depolarization is likely to use other factors. Therefore, further studies are required to understand how androgen inhibits the mitochondrial amplification of death receptor-mediated caspase activation.
Lignans are characterized as structurally similar to endogenous estrogens and belong to the group of phytoestrogens. Epidemiological and experimental data suggest that lignans have beneficial effects on human health because of their estrogenic and anti-estrogenic, anti-oxidative, anti-microbial and anti-carcinogenic properties (reviewed by McCann et al., 2005 and Adlercreutz, 2007) . The molecular mechanism behind anticancer activity of lignans is not yet well characterized. Lignans have been reported to induce downregulation of the anti-apoptotic Bcl-2 proteins (Hausott et al., 2003) and to inhibit casein kinase II and protein kinase C a (Yokoyama et al., 2003) . They can act as antioxidants protecting cells from oxidative stress (Kitts et al., 1999) , or as inhibitors of steroid metabolizing Lignans sensitize prostate cancer cells to TRAIL E Peuhu et al enzymes (Adlercreutz et al., 1993) . Chen et al. (2007) recently showed that ENL induces spontaneous apoptosis of LNCaP cells. The apoptotic mechanism was suggested to involve caspase activation through mitochondrial depolarization. Concomitantly, downregulation of Akt phosphorylation was observed, but no direct relationship or a possible mediator between these events was provided (Chen et al., 2007) . We did not observe spontaneous apoptosis during the 24-h exposure by any of the lignans used in this study. The dose of MAT used in the LNCaP cells did not either induce apoptosis whereas combination with low concentrations of TRAIL was lethal to cells. More recent report shows that ENL inhibits insulin-like growth factor-1 receptor signaling, Akt activity and cell migration in PC3 prostate cancer cells (Chen et al., 2009) . These results support the view that the anticancer activity of lignans is largely because of their ability to inhibit the Akt signaling. Whether this action is direct or indirect, like through the inhibition of the insulin-like growth factor-1 receptor signaling, remains to be elucidated.
To our knowledge, this is the first report showing that lignans can influence death receptor signaling by inhibiting downstream survival mechanisms such as Akt activity, thus, providing a new mechanism for anticancer activity of lignans. Therapeutic strategies that target the PI3K/ Akt pathway may be especially useful in treatment of prostate cancer. The combination of lignans and TRAIL has therapeutic potential against hormone-dependent prostate cancer and deserves further pre-clinical testing. This possibility is currently under investigation.
Materials and methods
Cell culture and reagents
The LNCaP prostate cancer cells (clone FGC; EACC) were cultivated in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO, USA). Medium was supplemented with 10% fetal calf serum (BioClear, Wiltshire, UK), 2 mM L-glutamin, 100 U/ml penicillin, 100 mg/ml streptomycin and 1 mM sodium pyruvate (SigmaAldrich). Two days after LNCaP seeding the medium was changed to phenol red free RPMI-1640 (Invitrogen, Carlsbad, CA, USA) with or without 1 nM synthetic androgen ([7a,17b]-17-hydroxy-7,17-dimethylestr-4-en-3-one) . This medium was supplemented with 10% charcoal/dextran-treated fetal bovine serum (Hyclone, Logan, UT, USA), L-glutamin, penicillin and streptomycin. The cells were incubated with MAT, ENL, hydroxymatairesinol or solvent control before apoptosis induction. Lignans were stored at þ 4 1C in 100 mM stock solutions in ethanol.
Plasmid construction and DNA transfection
The coding sequence for a constitutively active gag-Akt (kindly provided by Julian Downward) was amplified from the pSG5-PKB GAG vector by PCR and cloned in-frame into pEGFP-N1 vector (Clontech, Mountain View, CA, USA) in EcoRI and KpnI sites. LNCaP cells were seeded on 24-well plates 1 day before lipofection and grown to 30-50% confluency. The JetPEI transfection complexes (PolyPlus-transfection SA, Illkirch, France) were prepared and transfected according to the manufacturer's protocol. Empty pEGFP-N1 vector was transfected to control cells. Twenty hours post-transfection, the culture mediums were replaced by medium with or without androgen and the cells were cultured for further 24 h.
Assessment of apoptosis
LNCaP cells were treated with 0-100 mM lignans or solvent control for 1 h after which recombinant human isoleucine zipper-TRAIL (izTRAIL; a kind gift from H Walczak) was added to cells at indicated concentrations. Twenty hours later, the floating attached cells were collected and analysed for apoptosis. The cells were disrupted and the nuclei labeled for DNA content with propidium iodide (Sigma-Aldrich). The samples were analysed by flow cytometry (FL-2 channel, FACSCalibur; BD Pharmingen, San Diego, CA, USA) and the fraction of sub-G 0 /G 1 events (nuclear fragmentation) was detected as a measure of apoptotic cell death. For further examination of nuclear integrity, the cells were washed once in phosphate-buffered saline and fixed for 15 min in 3% paraformaldehyde. Cytospin (Thermo Scientific, Waltham, MA, USA) preparations were made and mounted in DAPI Vectashield (Vector Laboratories, Burlingame, CA, USA). The nuclei were viewed with Leica DMRE fluorescence microscope (40 Â objective) and the images were collected with Wasabi (1.4) software. Activated caspase-3 in cells was labeled with phycerythrin-conjugated antibody according to manufacturer's protocol (BD Pharmingen) and analysed by FACSCalibur flow cytometer (FL-2, FSC). For flow cytometric analysis of transfected LNCaP cells GFP-positive cells were gated (FL-1) and measured for caspase-3 activation (FL-2). For doxorubicin-induced apoptosis LNCaP cells were treated with 0.2 or 1 mM doxorubicin (Sigma-Aldrich) for 20 h.
TRAIL-R DISC immunoprecipitation
To stimulate TRAIL receptors LNCaP cells were detached and pelleted (1000 revolutions per minute. for 10 min) and resuspended in 1 ml of the collected medium. Later, 1 mg izTRAIL was added to the cell suspension. The cells were incubated at 37 1C for 15-60 min after which the reaction was stopped by adding 10 ml of ice-cold phosphate-buffered saline. Control cells were incubated without TRAIL at 37 1C for 60 min. After washing, the cells were lysed in 1ml of lysis buffer (20mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 0.2% Nonidet P40, and complete protease inhibitor mixture (Roche, Basel, Switzerland)) for 30 min on ice. The cell debris was removed by centrifugation at 15 000 g for 15 min at 4 1C. Equal amount of protein from each sample was precleared with Sepharose CL-4B for 1,5 h at 4 1C. A total of 2.5 mg of monoclonal anti-TRAIL-R1 (Clone HS101; Alexis, San Diego, CA, USA) and 2.5 mg of monoclonal anti-TRAIL-R2 (Clone HS201, Alexis) were added to samples and immunoprecipitated with 15 ml of protein G beads (Amersham Biosciences, Buckinghamshire, UK) for 2.5 h at 4 1C. The beads were washed six times with lysis buffer, resuspended in 3 Â Laemmli sample buffer, and finally boiled for 5 min. The immunoprecipitated samples and corresponding cell lysates (input) were analysed by 10% Criterion sodium dodecyl sulfate-polyacrylamide gel electrophoresis (BioRad, Hercules, CA, USA). Western blot analysis was performed using anti-FADD (BD Transduction Laboratories, Lexington, KY, USA), caspase-8 (clone C15; Alexis) and anti-DR5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The results are representative of three independent experiments. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting Whole cell lysates were prepared by lysing floating and attached cells in Laemmli sample buffer and boiling the samples for 10 min after which proteins were separated with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blotting was performed using antibodies against poly (ADP-ribose) polymerase (clone C-2-10; Sigma-Aldrich), Bid, Bax, Bim Akt and phospho(Ser473)-Akt (Cell Signalling Technology, Davers, MA, USA), Bcl XL (Santa Cruz Biotechnology), Actin (clone AC-40; Sigma-Aldrich) and c-FLIP (clone NF6; Alexis). Horseradish peroxidase-conjugated secondary antibodies were from Southern Biotechnology Associates (Birmingham, AL, USA), Promega (Madison, WI, USA) and Amersham Biosciences. The results were visualized using the ECL method (Amersham Biosciences) on X-ray film. The presented western blot results are representative of at least three independent experiments. For densitometric analysis of western blots, the X-ray films were scanned and the analysis was carried out with the MCID M5 þ software. The values were normalized to the untreated control sample, which was given the value 1. The histogram presents a relative decrease in pAkt/Akt ratio compared with control cells.
Tumor necrosis factor-related apoptosis-inducing ligand receptor cell surface expression Surface expression of TRAIL receptors was evaluated by indirect immunostaining using the anti-TRAIL-R1 (clone HS101), anti-TRAIL-R2 (clone HS201), anti-TRAIL-R3 (clone HS301) and anti-TRAIL-R4 (clone HS402) primary antibodies followed by Alexa 488 conjugated anti-mouse secondary antibody (Alexis). Nonspecific fluorescence was assessed using the secondary antibody only. Flow cytometric analyses were performed using a FACSCalibur and the mean fluorescence intensity of the FL-1 channel was measured.
Mitochondrial depolarization
Tetramethylrhodamine, methyl ester ( Invitrogen) was stored as 20 mM dimethylsulfoxide stock and diluted in medium before use. Floating and trypsinized cells were incubated in 20 nM tetramethylrhodamine for 10 min in 37 1C waterbath. The cells were placed on ice and analysed immediately by FACSCalibur flow cytometer (BD Pharmingen).
